# Dabogratinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dabogratinib

> Dabogratinib, sponsored by Tyra Biosciences, Inc. (TYRA): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | dabogratinib |
| Codes | TYRA-300 |
| Sponsor | Tyra Biosciences, Inc. (TYRA) https://sec-api.dev/companies/tyra/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### Oct 2024: interim data readout

- Status: completed, positive. Date confidence: month.
- First seen 2026-03-02, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001193125-26-085490): "In October 2024, we reported interim data showing a 50% response rate (5/10) in FGFR3 positive patients who received 90 mg daily of oral dabogratinib, with a 100% disease control rate, and favorable safety results demonstrating infrequent FGFR2 and 1 associated toxicities." https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm

### Mar 2025: trial start

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-03-19, last confirmed 2025-03-19.
- SEC Form 10-K (accession 0001410578-25-000377): "TYRA300 plans to start a Phase II study for achondroplasia with open growth plates in March 2025." https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm

### 2H 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-11-05, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-085399): "The Company remains on track and is expected to report interim results from the safety sentinel cohort - which will include 6-month average height velocity data and safety results - in 2H 2026." https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-266916): "The Company remains on track to report interim results from the safety sentinel cohort in 2H 2026." https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dabogratinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dabogratinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dabogratinib

```bibtex
@misc{secapidev_pdufa_dabogratinib_20261116,
  title        = {Dabogratinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dabogratinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dabogratinib_20261116","title":"Dabogratinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dabogratinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
